New Phase Research and Development LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$2,270,388	1
2024	Research	$44,540	25
2023	Research	$37,955	14
2022	Research	$19,606	3
2021	Research	$28,854	14
2020	Research	$2,002	1

Breakdown

Who paid Research payments · program years 2020–2025

Amgen Inc. $2,270,388 1 payment
Chiesi USA, Inc. $96,028 43 payments
GlaxoSmithKline, LLC. $18,468 4 payments
GRT US Holding, Inc. $18,460 10 payments

Studies the money was for Research payments · program years 2020–2025

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight $2,270,388 1 payment
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $44,540 25 payments
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $28,326 8 payments
A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Cont $18,468 4 payments
Av001 $18,460 10 payments
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) $9,629 6 payments
A 52-Week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500) Study to Evaluate the Efficacy and Safety of Two Doses of Chf6001 Dpi (Tanimilast) As Add-On to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (Pillar) (Pi $7,019 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.